



LOYOLA  
UNIVERSITY  
HEALTH SYSTEM

Loyola University Chicago

Loyola University Medical Center  
2160 South First Avenue  
Maywood, Illinois 60153

August 27, 2008

J-9  
MS-16

Ms. Tara Weidner  
US Nuclear Regulatory Commission

45-01099-01  
03003303

Dear Ms. Weidner:

I wish to inform you that Richard Garza MD has been approved by the Loyola University Medical Center Radiation Control Committee for use of their HDR unit. Dr. Garza is fully board certified and has been approved for all of the procedures and isotopes specified on the attached permit.

Sincerely,

*Kevin W Corrigan*

Kevin W Corrigan PhD  
Radiation Safety Officer

Attachment

**LOYOLA UNIVERSITY MEDICAL CENTER  
RADIOISOTOPE PERMIT  
(Human Use)**

A permit is hereby issued authorizing the individual(s) named herein to acquire and use the radioisotopes listed below, at the locations and for the purposes designated below. This permit is subject to all policies of Loyola University Medical Center, governing radioisotope possession and use. It is also subject to the provisions of 32 Illinois Administrative Code: Chapter II, Illinois Emergency Management Agency/Division of Nuclear Safety. Radioisotopes specified herein shall be used only on the premises and by or under the supervision of the named individuals.

1. NAME: BAHMAN EMAMI, M.D. et al  
2. DEPARTMENT: Radiation Oncology

3. PERMIT NUMBER: 3-32009-23-O  
4. EXPIRATION DATE: 3-30-2009


5. RADIOISOTOPES	6. CHEMICAL/PHYSICAL FORM	7. MAXIMUM POSSESSION
I-125/Pd-103	Sealed Sources approved for treatment	As needed
I-125	Iotrex	As needed
Ir-192	Sealed Sources (i.e. seeds) approved for treatment	As needed
Cs-137	Sealed Treatment Tubes (Only one on hand as of 3/1/07)	As needed
Sr-90	Eye Applicators	100 mCi
Ir-192	HDR Afterloader Sources (2)	30 Ci
Cs-137	One dose calibrator sealed standard	2.3 mCi


8. AUTHORIZED USE: Cs-137 and/or Ir-192 to be used for treatments employing afterloading of sources in patient room. I-125, Pd-103 seeds to be used per protocols approved by Radiation Control Committee for permanent implant therapy. I-125 Iotrex to be used per protocol approved by RCC for brain tumor treatment. Sr-90 eye applicators to be used for treatment by physicians approved to use them, according to protocols approved by RCC. Ir-192 HDR afterloader to be employed for treatment by physicians approved by RCC to use this device.

By this permit the following physicians are also individually approved as independent authorized users: Kevin Albuquerque, MD, Edward Melian, MD, Suneel Nagda, MD, Richard Garza MD, and Sarada Reddy, MD. Other physicians require approval by RCC before using sources for patient treatment.

The following individuals are approved to function as authorized Medical Physicists under this permit: Anil Sethi, PhD, Ming Xu, PhD, Ming Gao, PhD, Yong Ke, PhD, and Iris Rusu, MS. Other physicists require prior approval by RCC before independently carrying out the duties requiring an authorized medical physicist.

  
KEVIN W. CORRIGAN, Ph.D.  
Radiation Safety Officer

  
DENISE PUNKA

  
ANIL SETHI, Ph.D.


  
MARC BORGE, M.D.

  
SUSAN BAKER PhD

Approved By:

  
ROBERT H. WAGNER, M.D. Chairman  
Radiation Control Committee

  
FRAN FRANK, R.N.

  
ELLEN GAYNOR, MD

  
Mr. ALAN MORETTI